Galapagos Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Paul Stoffels

Chief Executive Officer (CEO)

€2.0m

Compensación total

Porcentaje del salario del CEO	38.0%
Permanencia del CEO	2yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	2yrs

Actualizaciones recientes de la dirección

Recent updates

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Mar 07

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Oct 10

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Oct 03

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Jun 04

Galapagos reports Q1 results

May 06

Galapagos: Market Values Pipeline Below $0

Dec 30

Galapagos candidate shows positive action in IPF proof-of-concept study

Nov 30

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Galapagos Is A Buy Despite Setback In The U.S.

Oct 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Stoffels en comparación con los beneficios de Galapagos?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€2m	€750k	-€4m
Sep 30 2023	n/a	n/a	-€153m
Jun 30 2023	n/a	n/a	-€157m
Mar 31 2023	n/a	n/a	-€181m
Dec 31 2022	€1m	€563k	-€71m

Compensación vs. Mercado: Paul($USD1.59M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.59M).

Compensación vs. Ingresos: La compensación de Paul ha aumentado mientras la empresa no es rentable.

CEO

Paul Stoffels (61 yo)

2yrs

Permanencia

€1,971,286

Compensación

Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paulus Stoffels	CEO, Chairman	2yrs	€1.97m	sin datos
Thad Huston	Executive VP	less than a year	sin datos	sin datos
Sofie Van Gijsel	Head of Investor Relations	no data	sin datos	sin datos
Valeria Cnossen	Executive VP & General Counsel	no data	sin datos	sin datos
Marieke Vermeersch	Head of Corporate Communication	no data	sin datos	sin datos
Annelies Missotten	Executive VP & Chief Human Resources Officer	no data	sin datos	sin datos
Ellen Aar	Head of Development	no data	sin datos	sin datos
Philippe Alen	Senior VP & Head of Business Development	2.3yrs	sin datos	sin datos
Dirk De Naeyer	Head of Development Operations	no data	sin datos	sin datos
Alice Dietrich	Head of Medical Affairs	no data	sin datos	sin datos
Pierre Raboisson	Head of Small Molecules Discovery & Senior VP	1.8yrs	sin datos	sin datos
Patrik Ringblom	Head of Strategy & US Lead	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: GLPGEl equipo directivo de la empresa no se considera experimentado ( 1.9 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paulus Stoffels	CEO, Chairman	2yrs	€1.97m	sin datos
Simon Sturge	Independent Non-Executive Director	less than a year	€32.37k	0.00027% € 5.2k
Jerome Contamine	Lead Independent Non-Executive Director	2yrs	€150.00k	0.0015% € 29.4k
Andrew Dickinson	Non-Executive Non-Independent Director	less than a year	sin datos	sin datos
Linda Higgins	Non-Executive Non-Independent Director	4.5yrs	sin datos	sin datos
Susanne Schaffert	Non-Executive Independent Director	less than a year	€59.85k	0.00055% € 10.6k
Peter Guenter	Independent Non-Executive Director	5yrs	€115.00k	0.0030% € 58.0k
Elisabeth Svanberg	Independent Non-Executive Director	4yrs	€138.75k	0.0029% € 54.9k
Daniel Baker	Non-Executive Independent Director	2yrs	€117.36k	0.0015% € 29.0k

2.0yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: GLPGno se consideran experimentados ( 1.7 años de permanencia media), lo que sugiere un nuevo consejo.

Galapagos Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Galapagos NV Announces Board Changes

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos NV Announces Board Changes

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Recent updates

Galapagos NV Announces Board Changes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

Galapagos: Can The Company Turn Around?

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Galapagos: A History Of Disruptive Failures

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos: The Investment Thesis Is More Appealing Than Ever

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos reports Q1 results

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Galapagos: Market Values Pipeline Below $0

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos candidate shows positive action in IPF proof-of-concept study

Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million.

Galapagos NV Announces Dosing of the First Psoriasis Patient in the Phase 1B Trial with GLPG3667

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Gilead Sciences, Inc. and Galapagos NV Announce the Application for A New Indication to the Approved License

Galapagos NV Unveils the Toledo Target Family as a Series of Salt-Inducible Kinase Inhibitors

Galapagos Is A Buy Despite Setback In The U.S.

Galapagos and Servier Report Topline Results for Roccella Phase 2 Clinical Trial with Glpg1972/S201086 in Knee Osteoarthritis Patients

Phase 2B/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Galapagos Announces First Dosing with Toledo compound GLPG3970 in psoriasis trial

Galapagos NV announces European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults with Moderate to Severe Active Rheumathoid Arthritis

Análisis de compensación del CEO

CEO